|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Accordingly, we conducted a first study to investigate the diagnostic and prognostic significance of CPA4 in the case of breast cancer (BC), the most common form of malignancy in women.
|
30875843 |
2019 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Knock-down of CPA4 decreased cancer cell proliferation as detected by MTT and clone formation assays.
|
31058377 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Carboxypeptidase A4 (CPA4) is a novel cancer-related gene that is aberrantly expressed in various malignant tumors.
|
31279884 |
2019 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Furthermore, high CPA4 expression in TNBC cases was associated with low expression of E‑cadherin and with the expression of cancer stem cell markers (high CD44/low CD24).
|
30628666 |
2019 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Overexpression of CPA4 was closely associated with the putative cancer stem cell marker ALDH1A1 and might be used as an independent prognostic factor in ESCC.
|
28475748 |
2017 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
This study is aimed at investigating the expression of carboxypeptidaseA4 (CPA4) and aldehyde dehydrogenase 1A1 (ALDH1A1) in esophageal squamous cell carcinoma (ESCC) tumor tissues and analyzed their association and clinical significance.
|
28475748 |
2017 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
In contrast, in 9L tumors expressing P450 2B11, a low K(m) CPA 4-hydroxylase, intratumoral 4-OH-CPA levels were higher than in blood, liver and P450-deficient tumors.
|
17853921 |
2007 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
When the results of patient group were statistically analyzed based on subgrouping by tumor characteristics, the measured CPA4 mRNA levels showed significant difference with respect to the molecular subtype (<i>p</i> = 0.006), pN status (<i>p</i> = 0.023), and pathological stage (<i>p</i> = 0.039), while the serum CPA4 measurements differed significantly in terms of pathological type only (<i>p</i> = 0.024).
|
30875843 |
2019 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
These data suggest that CPA4 expression leads to poor prognoses by regulating tumour proliferation and the expression of stem cell characteristics and may therefore serve as a potential therapeutic target of HCC.
|
31058377 |
2019 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Consistent with these observations, we generated xenograft tumor models to confirm that CPA4 downregulation suppressed NSCLC cell growth.
|
31397502 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Overexpression of CPA4 was closely associated with the putative cancer stem cell marker ALDH1A1 and might be used as an independent prognostic factor in ESCC.
|
28475748 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Knock-down of CPA4 decreased cancer cell proliferation as detected by MTT and clone formation assays.
|
31058377 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Carboxypeptidase A4 (CPA4) is a novel cancer-related gene that is aberrantly expressed in various malignant tumors.
|
31279884 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Accordingly, we conducted a first study to investigate the diagnostic and prognostic significance of CPA4 in the case of breast cancer (BC), the most common form of malignancy in women.
|
30875843 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Furthermore, high CPA4 expression in TNBC cases was associated with low expression of E‑cadherin and with the expression of cancer stem cell markers (high CD44/low CD24).
|
30628666 |
2019 |
|
Asthma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Genes related to epithelial repair and mast cell infiltration including beta-tryptase and carboxypeptidase A3 were upregulated by exercise challenge in the asthma group with EIB.
|
20052409 |
2010 |
|
Asthma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A signature of 6 genes, including Charcot-Leydon crystal protein (CLC); carboxypeptidase A3 (CPA3); deoxyribonuclease I-like 3 (DNASE1L3); IL-1β (IL1B); alkaline phosphatase, tissue-nonspecific isozyme (ALPL); and chemokine (C-X-C motif) receptor 2 (CXCR2), was reproducible and could significantly (P < .0001) discriminate eosinophilic asthma from other phenotypes, including patients with noneosinophilic asthma (AUC, 89.6%), paucigranulocytic asthma (AUC, 92.6%), or neutrophilic asthma (AUC, 91.4%) and healthy control subjects (AUC, 97.6%), as well as discriminating patients with neutrophilic asthma from those with paucigranulocytic asthma (AUC, 85.7%) and healthy control subjects (AUC, 90.8).
|
24582314 |
2014 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Using whole transcriptome analysis and a lentiviral short hairpin RNA screening library, carboxypeptidase A4 (CPA4) was identified as a novel marker in breast cancer and a therapeutic target in triple‑negative breast cancer (TNBC) in the present study.
|
30628666 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
We conclude that CPA4 is diagnostically and prognostically not futile when used in combination with the other considerations and measurements in breast cancer.
|
30875843 |
2019 |
|
Russell-Silver syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
As a Silver-Russell syndrome (SRS) locus has been proposed to be located to a region near MEST and to be involved in imprinting, CPA4 would have been a candidate gene for SRS.
|
12552318 |
2003 |
|
Russell-Silver syndrome
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
As CPA4 has a potential role in cell proliferation and differentiation, two preferentially expressed copies in mUPD patients with SRS syndrome would result in excess expression and could alter the growth profiles of these subjects and give rise to intrauterine growth restriction.
|
12676894 |
2003 |
|
Adult Liver Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis showed high CPA4 expression in the liver cancer cell line Bel7402 and low expression in HepG2 cells.
|
31058377 |
2019 |
|
Adult Liver Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Multivariate Cox regression model showed that CPA4 was an independent prognostic factor for patients with liver cancer.
|
28123604 |
2017 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis showed high CPA4 expression in the liver cancer cell line Bel7402 and low expression in HepG2 cells.
|
31058377 |
2019 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Multivariate Cox regression model showed that CPA4 was an independent prognostic factor for patients with liver cancer.
|
28123604 |
2017 |